Mechanisms of resistance of Plasmodium falciparum to antimalarial drugs

Microbes and Infection

Volumn 4, Issue 2, 2002, Pages 165-174

  Hyde, John E ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Antifolates; Artemisinin; Atovaquone; Chloroquine; Halofantrine; Mefloquine; Quinine

Indexed keywords

1,4 NAPHTHOQUINONE DERIVATIVE; AMINO ACID; ARTEETHER; ARTEMETHER; ARTEMISININ DERIVATIVE; ARTESUNATE; ATOVAQUONE; ATOVAQUONE PLUS PROGUANIL; CHLOROQUINE; CYCLOGUANIL; DAPSONE; DIHYDROARTEMISININ; DIHYDROFOLATE REDUCTASE; DIHYDROPTEROATE SYNTHASE; FLUOROOROTIC ACID; FOLIC ACID; FOLIC ACID ANTAGONIST; GLYCOPROTEIN P; HALOFANTRINE; HEMOZOIN; ISOPROTEIN; MEFLOQUINE; PROGUANIL; PYRIMETHAMINE; QUININE; SULFADOXINE; SULFALENE; VERAPAMIL;

AMINO ACID SUBSTITUTION; ANTIMALARIAL ACTIVITY; CHEMOPROPHYLAXIS; CHEMOTHERAPY; CHROMOSOME 7; CROSS RESISTANCE; DRUG EFFICACY; DRUG MECHANISM; ENZYME ANALYSIS; ENZYME STRUCTURE; FOLIC ACID BLOOD LEVEL; GENE MUTATION; HOST PARASITE INTERACTION; HUMAN; MALARIA FALCIPARUM; NONHUMAN; OPEN READING FRAME; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; REVIEW; X RAY DIFFRACTION;

ANIMALS; ANTIMALARIALS; DRUG RESISTANCE; FOLIC ACID ANTAGONISTS; GENES, PROTOZOAN; HUMANS; MALARIA; PLASMODIUM FALCIPARUM;

CINCHONA PUBESCENS; PLASMODIUM FALCIPARUM;

EID: 0036188538     PISSN: 12864579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1286-4579(01)01524-6     Document Type: Review

References (103)

1. The dynamics of drug resistance in Plasmodium falciparum
2. Epidemiology of drug resistance in malaria
3. Molecular cloning and sequence analysis of the Plasmodium falciparum dihydrofolate reductase-thymidylate synthase gene
4. Synergistic antimalarial activity of pyrimethamine and sulfadoxine against Plasmodium falciparum in vitro
5. Sequence variation of the hydroxymethyldihydropterin pyrophosphokinase - Dihydropteroate synthase gene in lines of the human malaria parasite, Plasmodium falciparum, with differing resistance to sulfadoxine
6. Primary structure and expression of the dihydropteroate synthetase gene of Plasmodium falciparum
7. Amino-acid changes linked to pyrimethamine resistance in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum
8. Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria
9. Characterization of the dihydrofolate reductase-thymidylate synthetase gene from human malaria parasites highly resistant to pyrimethamine
10. The dihydrofolate reductase-thymidylate synthetase gene in the drug resistance of malaria parasites
11. Kinetic and molecular properties of the dihydrofolate reductase from pyrimethamine-sensitive and pyrimethamine-resistant clones of the human malaria parasite Plasmodium falciparum
12. Antifolate-resistant mutants of Plasmodium falciparum dihydrofolate reductase
13. Analysis in yeast of antimalaria drugs that target the dihydrofolate reductase of Plasmodium falciparum
14. Antifolate resistance due to new and known Plasmodium falciparum dihydrofolate reductase mutations expressed in yeast
15. Transformation of Plasmodium falciparum malaria parasites by homologous integration of plasmids that confer resistance to pyrimethamine
16. Gene mutations and amplification of dihydrofolate reductase genes in parasites grown in vitro in presence of pyrimethamine
17. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance
18. Mutations in dihydropteroate synthase are responsible for sulfone and sulfonamide resistance in Plasmodium falciparum
19. Resistance to antifolates in Plasmodium falciparum monitored by sequence analysis of dihydropteroate synthetase and dihydrofolate reductase alleles in a large number of field samples of diverse origins
20. Point mutations in the dihydrofolate reductase and dihydropteroate synthetase genes and in vitro susceptibility to pyrimethamine and cycloguanil of Plasmodium falciparum isolates from Papua New Guinea
21. Molecular evidence of greater selective pressure for drug resistance exerted by the long-acting antifolate pyrimethaminel/sulfadoxine compared with the shorter-acting chlorproguanil/dapsone on Kenyan Plasmodium falciparum
22. Molecular assays for surveillance of antifolate-resistant malaria
23. A modified in vitro sulfadoxine susceptibility assay for Plasmodium falciparum suitable for investigating Fansidar resistance
24. Chloroquine resistance not linked to mdr-like genes in a Plasmodium falciparum cross
25. An RFLP map of the Plasmodium falciparum genome, recombination rates and favored linkage groups in a genetic cross
26. Sulfadoxine resistance in the human malaria parasite Plasmodium falciparum is determined by mutations in dihydropteroate synthetase and an additional factor associated with folate utilization
27. Allelic exchange at the endogenous genomic locus in Plasmodium falciparum proves the role of dihydropteroate synthase in sulfadoxine-resistant malaria
28. In vitro activities of and mechanisms of resistance to antifol antimalarial drugs
29. Antagonism of sulfadoxine and pyrimethamine antimalarial activity in vitro by para-aminobenzoic acid, para-aminobenzoylglutamic acid and folic acid
30. Utilization of exogenous folate in the human malaria parasite Plasmodium falciparum and its critical role in antifolate drug synergy
31. Selection and synergy in Plasmodium falciparum
32. Lead discovery of inhibitors of the dihydrofolate reductase domain of Plasmodium falciparum dihydrofolate reductase-thymidylate synthase
33. Rational drug design approach for overcoming drug resistance: Application to pyrimethamine resistance in malaria
34. Towards an understanding of drug resistance in malaria: Three-dimensional structure of Plasmodium falciparum dihydrofolate reductase by homology building
35. Antimalarial drug discovery: Development of inhibitors of dihydrofolate reductase active in drug resistance
36. Crystal structure of the anti-bacterial sulfonamide drug target dihydropteroate synthase
37. Structure and function of the dihydropteroate synthase from Staphylococcus aureus
38. Crystal structure of Mycobacterium tuberculosis 6-hydroxymethyl-7,8-dihydropteroate synthase in complex with pterin monophosphate: New insight into the enzymatic mechanism and sulfa-drug action
39. Sulfa-drug resistance in Plasmodium falciparum
40. Identification of the acidic compartment of Plasmodium falciparum-infected human erythrocytes as the target of the antimalarial drug chloroquine
41. An integrated model of chloroquine action
42. Plasmodium falciparum in owl monkeys: Drug resistance and chloroquine binding capacity
43. Efflux of chloroquine from Plasmodium falciparum - Mechanism of chloroquine resistance
44. Kinetic modelling of chloroquine uptake by malaria-infected erythrocytes
45. Relationship of global chloroquine transport and reversal of resistance in Plasmodium falciparum
46. Access to hematin: The basis of chloroquine resistance
47. Susceptibility of Plasmodium falciparum to 5 drugs - An in vitro study of isolates mainly from Thailand
48. Studies of resistance to chloroquine, quinine, amodiaquine and mefloquine among Philippine strains of Plasmodium falciparum
49. Cross-resistance between mefloquine and halofantrine
50. Central role of hemoglobin degradation in mechanisms of action of 4-aminoquinolines, quinoline methanols, and phenanthrene methanols
51. Cellular uptake of chloroquine is dependent on binding to ferriprotoporphyrin IX and is independent of NHE activity in Plasmodium falciparum
52. A common mechanism for blockade of heme polymerization by antimalarial quinolines
53. Genetic mapping of the chloroquine-resistance locus on Plasmodium falciparum chromosome 7
54. A genetic map and recombination parameters of the human malaria parasite Plasmodium falciparum
55. Complex polymorphisms in an ∼ 330 kDa protein are linked to chloroquine-resistant P. falciparum in Southeast Asia and Africa
56. Allelic modifications of the cg2 and cg1 genes do not alter the chloroquine response of drug-resistant Plasmodium falciparum
57. Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance
58. A molecular marker for chloroquine-resistant falciparum malaria
59. Reversal of chloroquine resistance in Plasmodium falciparum by verapamil
60. Amplification of the multidrug resistance gene in some chloroquine-resistant isolates of P. falciparum
61. Amplification of a gene related to mammalian mdr genes in drug-resistant Plasmodium falciparum
62. Characterization of the pfmdr2 gene for Plasmodium falciparum
63. Plasmodium falciparum - The pfmdr2 protein is not overexpressed in chloroquine-resistant isolates of the malaria parasite
64. The ATP-binding cassette (ABC) gene family of Plasmodium falciparum
65. Several alleles of the multidrug-resistance gene are closely linked to chloroquine resistance in Plasmodium falciparum
66. Amplification of pfmdr1 associated with mefloquine and halofantrine resistance in Plasmodium falciparum from Thailand
67. Analysis of pfmdr1 and drug susceptibility in fresh isolates of Plasmodium falciparum from subsaharan Africa
68. Plasmodium falciparum: Molecular characterization of multidrug-resistant Cambodian isolates
69. A P-glycoprotein homolog of Plasmodium falciparum is localized on the digestive vacuole
70. Plasmodium falciparum: In vitro chloroquine susceptibility and allele-specific PCR detection of Pfmdr1 (Asn)86(Tyr) polymorphism in Lambarene, Gabon
71. Pfmdr1 (Asn)1042(Asp) and (Asp)1246(Tyr) polymorphisms, thought to be associated with chloroquine resistance, are present in chloroquine-resistant and -sensitive Brazilian field isolates of Plasmodium falciparum
72. Pgh1 modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum
73. Increased sensitivity to the antimalarials mefloquine and artemisinin is conferred by mutations in the pfmdr1 gene of Plasmodium falciparum
74. Analysis of mefloquine resistance and amplification of pfmdr1 in multidrug-resistant Plasmodium falciparum isolates from Thailand
75. Selection for high-level chloroquine resistance results in deamplification of the pfmdr1 gene and increased sensitivity to mefloquine in Plasmodium falciparum
76. Selection for mefloquine resistance in Plasmodium falciparum is linked to amplification of the pfmdr1 gene and cross-resistance to halofantrine and quinine
77. A strong association between mefloquine and halofantrine resistance and amplification, overexpression, and mutation in the P-glycoprotein gene homolog (pfmdr) of Plasmodium falciparum in vitro
78. In vitro selection of halofantrine resistance in Plasmodium falciparum is not associated with increased expression of Pgh1
79. Evidence for different mechanisms of chloroquine resistance in 2 Plasmodium species that cause human malaria
80. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo
81. Gametocytes, chloroquine pressure, and the relative parasite survival advantage of resistant strains of falciparum malaria in west Africa
82. Artemisinin and the antimalarial endoperoxides: From herbal remedy to targeted chemotherapy
83. Possible modes of action of the artemisinin-type compounds
84. The interaction of artemisinin with malarial hemozoin
85. Artemisinin (qinghaosu) - The role of intracellular hemin in its mechanism of antimalarial action
86. Reaction of antimalarial endoperoxides with specific parasite proteins
87. The Plasmodium falciparum translationally controlled tumor protein homolog and its reaction with the antimalarial drug artemisinin
88. The interaction of artemisinin with red-cell membranes
89. Artemisinin, an endoperoxide antimalarial, disrupts the hemoglobin catabolism and heme detoxification systems in malarial parasite
90. Effects of antimalarials and protease inhibitors on plasmodial hemozoin production
91. Mathematical modelling of the chemotherapy of Plasmodium falciparum malaria with artesunate: Postulation of 'dormancy', a partial cytostatic effect of the drug, and its implication for treatment regimens
92. Drug resistance in malaria parasites of animals and man
93. Mitochondrial protein import - Mechanisms, components and energetics
94. Atovaquone, a broad spectrum antiparasitic drug, collapses mitochondrial membrane potential in a malarial parasite
95. Resistance mutations reveal the atovaquone-binding domain of cytochrome b in malaria parasites
96. Mutations in Plasmodium falciparum cytochrome b that are associated with atovaquone resistance are located at a putative drug-binding site
97. Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand
98. Atovaquone and proguanil for Plasmodium falciparum malaria
99. Proguanil polymorphism does not affect the antimalarial activity of proguanil combined with atovaquone in vitro
100. Cycloguanil and its parent compound proguanil demonstrate distinct activities against Plasmodium falciparum malaria parasites transformed with human dihydrofolate reductase
101. A mechanism for the synergistic antimalarial action of atovaquone and proguanil
102. Variations in frequencies of drug resistance in Plasmodium falciparum
103. Spontaneous mutators in bacteria: Insights into pathways of mutagenesis and repair